A Canadian marijuana producer has told investors that current market pressures led to a disputed rights offering that caused a dramatic drop in value for the firm.

To appease investor sentiment about the new financing, the executive team of Zenabis Global (TSX:ZENA) hosted a call with shareholders on Tuesday (October 29). During the call, CEO Andrew Grieve addressed the market’s reaction to the company’s recently announced rights offering.


The leading executive called the rights offering a prudent approach to current capital market conditions seen among cannabis players.

The executive admitted it’s been an extremely difficult year for shareholders of the firm. He then pointed to general realities in the Canadian cannabis market — primarily the competition seen by producers like Zenabis from unregulated cannabis players.

Grieve said equity in the cannabis space has reduced for licensed producers; now, he explained, these companies are pursuing alternative capital raises by way of convertible debt financings.

In his opinion, given current market valuations, Zenabis currently trades at a “significant discount” compared to its peers in the public market.

Effectively, Zenabis plans to raise C$20.8 million by way of a rights offering to current shareholders. The raise is being done as a way to balance the cash holdings of the company — a move that is “in the best interest of shareholders,” according to the producer.

Grieve said that, given the rules of the Toronto Stock Exchange, starting on Wednesday (October 30) common shares of Zenabis will stop trading with an entitlement to a right; instead, the rights will trade separately on the Canadian exchange.

He said the two top questions the company has received since announcing the rights offering are why this method was chosen and how Zenabis settled the price of the rights, which give holders a common share entitlement at C$0.15.

“Zenabis determined that it was not in the best interest of shareholders to raise incremental debt from non-traditional sources, given additional debt would’ve increased cash burn until it became cash flow positive (and) increased our overall leverage, and given the requirement to raise convertible debt would’ve been meaningfully dilutive to shareholders,” Grieve told investors during the call.

In a previous email statement to the Investing News Network, Jonathan Anthony, director of corporate communications with Zenabis, said the company was pleased with the vote of confidence the offering provides since insiders at the firm are participating.

“That commitment is a real vote of confidence in the future of the business and we believe investors will respond positively,” he said. He added that the response from the market is outside of Zenabis’ control.

Zenabis shares dropped nearly 40 percent when it announced its rights deal last Thursday (October 24).

On Monday (October 29), leading up to the call with investors, shares of the firm bounced back with a 14 percent spike in Toronto. The company eventually finished the trading day at a price of C$0.29, representing a 16 percent spike.

Year-to-date, shares of Zenabis have collapsed 95.25 percent, resulting in a loss per share of C$5.71.

“(The rights offering) was done to offer shareholders the most compelling opportunity possible to maintain their ownership in the business,” Grieve said.

Don’t forget to follow usn@INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less